DREAMseq: Upfront Dual Immunotherapy More Efficacious Than Dual Targeted Therapy for <em>BRAF</em>V600-Mutant Metastatic Melanoma

2021 ◽  
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma

scholarly journals Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype

2014 ◽  
Vol 5 (3) ◽  
pp. 264-273 ◽  
Author(s):  
Kim H.T. Paraiso ◽  
Meghna Das Thakur ◽  
Bin Fang ◽  
John M. Koomen ◽  
Inna V. Fedorenko ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma

Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy

2021 ◽  
Vol 31 (3) ◽  
pp. 272-276
Author(s):  
Jens Tijtgat ◽  
Julia Katharina Schwarze ◽  
Gil Awada ◽  
Bart Neyns ◽  
Sandrine Aspeslagh
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma ◽  
Melanoma Patient ◽  
Braf V600e ◽  
Metastatic Melanoma Patient

scholarly journals Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma

2019 ◽  
Vol 10 ◽  
Author(s):  
Chune Yu ◽  
Xiaowei Liu ◽  
Jiqiao Yang ◽  
Min Zhang ◽  
Hongyu Jin ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma ◽  
Theory And Practice

scholarly journals Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma

2020 ◽  
Vol 33 (3) ◽  
pp. 390-402 ◽  
Author(s):  
Patricia M. LoRusso ◽  
Kurt Schalper ◽  
Jeffrey Sosman
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma

scholarly journals Targeted Therapy against Metastatic Melanoma Based on Self-Assembled Metal-Phenolic Nanocomplexes Comprised of Green Tea Catechin

2019 ◽  
Vol 6 (5) ◽  
pp. 1801688 ◽  
Author(s):  
Ke Li ◽  
Gao Xiao ◽  
Joseph J. Richardson ◽  
Blaise L. Tardy ◽  
Hirotaka Ejima ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma ◽  
Green Tea ◽  
Green Tea Catechin ◽  
Self Assembled

Frontline Therapy forBRAF-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?

2019 ◽  
pp. 564-571 ◽  
Author(s):  
Anna C. Pavlick ◽  
Leslie Fecher ◽  
Paolo A. Ascierto ◽  
Ryan J. Sullivan
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma ◽  
Initial Therapy ◽  
Combination Immunotherapy ◽  
Wild Type ◽  
Aggressive Disease ◽  
Multiple Factors ◽  
Secondary Endpoints ◽  
Frontline Therapy ◽  
Mutation Braf

Genetic analysis of melanoma has allowed us to identify a population of patients who have more aggressive disease and harbor the driver mutation BRAF. This mutation is found in approximately 50% of metastatic disease and provides a target for focused therapies to control this disease. These responses are usually brisk; however, they lack the durability of immunotherapy. Frontline therapy for patients with BRAF-mutated melanoma is not as straightforward as prescribing BRAF/MEK inhibitors. Prior trials of combination immunotherapy demonstrate similar responses and durability of responses in patients with BRAF wild-type as well as BRAF-mutated disease. Decisions about immunotherapy, targeted therapy, or the combination of immunotherapy with targeted therapy require an oncologist to evaluate multiple factors to select which treatment option is best for the patient. Trials for metastatic melanoma have included biomarkers as secondary endpoints and aim to identify some way to predict a response, or lack thereof, to therapy. Here, we discuss the utility and reliability of biomarkers in determining therapy for patients with BRAF-mutated metastatic melanoma and discuss combination immunotherapy with targeted therapy versus sequential immunotherapy/targeted therapy as well as which regimen should be implemented as initial therapy.

Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma

2018 ◽  
pp. 1 ◽  
Author(s):  
Marie Lamiaux ◽  
Camille Scalbert ◽  
Pauline Lepesant ◽  
Eve Desmedt ◽  
Carole Templier ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma ◽  
Skin Toxicity ◽  
Organ Damage

scholarly journals Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy

2020 ◽  
Vol 2020 ◽  
pp. 1-6 ◽  
Author(s):  
Caitlyn N. Myrdal ◽  
Srinath Sundararajan
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma ◽  
Checkpoint Inhibitors ◽  
Single Agent ◽  
Objective Response ◽  
Braf Inhibitor ◽  
Mek Inhibitor ◽  
Optimal Sequencing ◽  
The Right

Little is known about the optimal sequencing of targeted therapy and immunotherapy in the treatment of patients with BRAFV600-mutated metastatic melanoma. BRAF/MEK inhibition often has the benefit of rapid disease regression; however, resistance is frequently seen with long-term use. Treatment with immune checkpoint inhibitors offers the potential for long-term response but displays a lower rate of objective response. The benefit of synergy between therapies is apparent; however, there is limited data regarding optimal sequencing in the treatment of advanced melanoma. We present the case of a 62-year-old gentleman with advanced BRAFV600-mutated melanoma who followed an unconventional treatment path. After progressing on single-agent vemurafenib, he had response to multiple modalities of immunotherapy before progression. After, he had a substantial response to multiple BRAF/MEK inhibitor rechallenges before developing resistance. The patient is now stable after a retrial of combination immunotherapy. Our case illustrates that with the right sequencing of therapy, meaningful clinical responses can be elicited with rechallenging of targeted therapy and immunotherapy in metastatic melanoma.

Sign in / Sign up

Export Citation Format

Share Document